Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 16;11(16):e025339.
doi: 10.1161/JAHA.122.025339. Epub 2022 Aug 5.

Leadless or Conventional Transvenous Ventricular Permanent Pacemakers: A Nationwide Matched Control Study

Alexandre Bodin  1 , Nicolas Clementy  1 , Arnaud Bisson  1 , Bertrand Pierre  1 , Julien Herbert  1   2 , Dominique Babuty  1 , Laurent Fauchier  1
Affiliations

Leadless or Conventional Transvenous Ventricular Permanent Pacemakers: A Nationwide Matched Control Study

Alexandre Bodin et al. J Am Heart Assoc. .

Abstract

Background Leadless ventricular permanent pacemakers (leadless VVI or LPM) were designed to reduce lead-related complications of conventional VVI pacemakers (CPM). The aim of our study was to assess and compare real-life clinical outcomes within the first 30 days and during a midterm follow-up with the 2 techniques. Methods and Results This French longitudinal cohort study was based on the national hospitalization database. All adults (age ≥18 years) hospitalized in French hospitals from January 1, 2017 to September 1, 2020, who underwent a first LPM or CPM were included. The study included 40 828 patients with CPM and 1487 with LPM. After propensity score matching 1344 patients with CPM were matched 1:1 with patients treated with LPM. Patients with LPM had a lower rate of all-cause and cardiovascular death within the 30 days after implantation. During subsequent follow-up (mean: 8.6±10.5 months), risk of all-cause death in the unmatched population was significantly higher in the LPM group than in the CPM group, whereas risk of cardiovascular death and of endocarditis was not significantly different. After matching on all baseline characteristics including comorbidities (mean follow-up 6.2±8.7 months), all-cause death, cardiovascular death, and infective endocarditis were not statistically different in the 2 groups. Conclusions Patients treated with leadless VVI pacemakers had better clinical outcomes in the first month compared with the patients treated with conventional VVI pacing. During a midterm follow-up, risk of all-cause death, cardiovascular death, and endocarditis in patients treated with leadless VVI pacemaker was not statistically different after propensity score matching.

Keywords: leadless; pacemakers; transvenous.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Flow chart of the study patients.
VVI indicates ventricular permanent pacemaker.
Figure 2
Figure 2. Cumulative incidences for all‐cause death in unmatched (top panel) or matched (lower panel) patients during follow‐up.
HR indicates hazard ratio; and VVI, ventricular permanent pacemaker.
Figure 3
Figure 3. Cumulative incidences for cardiovascular death in unmatched (top panel) or matched (lower panel) patients during follow‐up.
HR indicates hazard ratio; and VVI, ventricular permanent pacemaker.
Figure 4
Figure 4. Cumulative incidences for first diagnosis of infective endocarditis in unmatched (top panel) or matched (lower panel) patients during follow‐up.
HR indicates hazard ratio; and VVI, ventricular permanent pacemaker.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cantillon DJ, Exner DV, Badie N, Davis K, Gu NY, Nabutovsky Y, Doshi R. Complications and health care costs associated with transvenous cardiac pacemakers in a Nationwide assessment. JACC Clin Electrophysiol. 2017;3:1296–1305. doi: 10.1016/j.jacep.2017.05.007 - DOI - PubMed
    1. Clémenty N, Carion PL, Léotoing L, Lamarsalle L, Wilquin‐Bequet F, Brown B, Verhees KJP, Fernandes J, Deharo J‐C. Infections and associated costs following cardiovascular implantable electronic device implantations: a nationwide cohort study. Europace. 2018;20:1974–1980. doi: 10.1093/europace/eux387 - DOI - PubMed
    1. Clémenty N, Fernandes J, Carion PL, de Léotoing L, Lamarsalle L, Wilquin‐Bequet F, Wolff C, Verhees KJP, Nicolle E, Deharo J‐C. Pacemaker complications and costs: a nationwide economic study. J Med Econ. 2019;22:1171–1178. doi: 10.1080/13696998.2019.1652186 - DOI - PubMed
    1. Reynolds D, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, Narasimhan C, Steinwender C, Brugada J, Lloyd M, et al. Micra transcatheter pacing study group. A leadless intracardiac transcatheter pacing system. N Engl J Med. 2016;374:533–541. doi: 10.1056/NEJMoa1511643 - DOI - PubMed
    1. Roberts PR, Clementy N, Al Samadi F, Garweg C, Martinez‐Sande JL, Iacopino S, Johansen JB, Vinolas Prat X, Kowal RC, Klug D, et al. A leadless pacemaker in the real‐world setting: the Micra transcatheter pacing system post‐approval registry. Heart Rhythm. 2017;14:1375–1379. doi: 10.1016/j.hrthm.2017.05.017 - DOI - PubMed